About
Coronis Partners is a leading Israeli Investment Company specializing in the biotechnology sector and focusing exclusively on highly select opportunities in the life sciences including therapeutics, diagnostic and agro-bio space. Coronis companies have demonstrated through superior management and financial planning - high growth, good financial stability and the ability to meet their development plans and goals. Since 2004, Coronis has invested over $10M in seven high quality portfolio companies. In 2007, four of Coronis companies issued public offerings BiondVax (TASE: BNDX) and Evogene (TASE: EVGN) in Tel Aviv; Rosetta Genomics (Nasdaq:ROSG) and Modigene (Nasdaq:MODG) at Nasdaq. Coronis performed partial exits in three of the four traded companies, with return on the initial price per share ranging between 5 to 6 fold in each of them (Evogene - Invested at $1 and Exited at $5; BiondVax - Invested at $0.45 and Exited at $2.26; Prolor - Invested at $1.5 and Exited at $8.6). The fifth company Glycominds has successfully completed a public offering in TASE in February 2011 (TASE: GLCM). Coronis Partners was active till the end of 2016.
Portfolio · 2
Investment activity
2 portfolio exits on record.
Portfolio by sector
Q&A
- What is Coronis Partners' primary investment focus?
- Coronis Partners is an Israeli investment company specializing in the biotechnology sector, with a focus on life sciences opportunities including therapeutics, diagnostics, and agro-bio.
- When was Coronis Partners founded and what is its operational status?
- Coronis Partners was founded in 2003 and was active until the end of 2016.
- Can you name some notable exits for Coronis Partners?
- Coronis Partners had an exit with Glycominds in April 2014, which was acquired by Medivie Therapeutic. Another notable exit was Rosetta Genomics, which had a public offering on NASDAQ in February 2007.
- What investment stages does Coronis Partners typically focus on?
- Coronis Partners primarily focuses on Pre-Seed investment stages.
- Which sectors have seen exits for Coronis Partners?
- All of Coronis Partners' exits have been in the Health Tech & Life Sciences sector.
- What is the geographic focus of Coronis Partners?
- Coronis Partners is headquartered in Ness Ziona, Israel.
- Who is a key team member at Coronis Partners?
- Udi Arad serves as the Chairman at Coronis Partners Ltd.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | coronis-partners.com/ |
|---|
Identifiers & details
| Founded | 2003 |
|---|
Radar intelligence
Web history (Wayback)
| Domain | coronis-partners.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|